Ignite Creation Date:
2024-05-05 @ 6:38 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00511446
Status:
COMPLETED
Last Update Posted:
2013-06-26
First Post:
2007-08-02
Brief Title:
Trial of Docetaxel Oxaliplatin and Capecitabine TEX in Advanced or Metastatic Gastric Cancer
Sponsor:
Martin-Luther-Universität Halle-Wittenberg
Organization:
Martin-Luther-Universität Halle-Wittenberg
Study Overview
Official Title:
Phase II Trial of Docetaxel Oxaliplatin and Capecitabine TEX in Advanced or Metastatic Gastric Cancer
Status:
COMPLETED
Status Verified Date:
2013-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Combination regimens of 3 active drugs have shown promising activity in treatment of metastatic gastric cancer Docetaxel combined with cisplatin and 5-fluorouracil FU yielded superior overall survival and response rates when compared to standard cisplatin and 5-FU However a toxicity profile showed the need for development of less toxic modifications In a prior phase I trial the maximum tolerated dose was defined In this phase II trial a first evaluation of activity will be performed
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None